The treatment of MPNST in patients with NF1 is challenging due to the aggressive course of the disease, the high tendency to relapse, and the limited efficacy of systemic therapies, involving oncologists, radiologists, surgeons, geneticists, and pathologists, to ensure comprehensive patient care. Here, NF1 is linked to malignant peripheral nerve sheath tumor.